Glaxo Wellcome Inc.
Division of GlaxoSmithKline PLC
www.gsk.com
Latest From Glaxo Wellcome Inc.
As Expected: Shareholders Back Bristol's $74bn Celgene Buy
With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.
Bristol/Celgene A Record-Setting Merger, If It Happens
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
Bristol/Celgene A Record-Setting Merger, If It Happens
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
Takeda/Shire Deal Stands Fifth Largest In Biopharma M&A
The $62.4bn price tag for Takeda’s acquisition of Shire is topped globally only by the Pfizer take-outs of Warner-Lambert and Wyeth, the merger that created GlaxoSmithKline, and Actavis’ purchase of Allergan.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
-
Adrian Hanna, SVP & CFO
Anthony Scullion, VP, Global Business Development
Robert M Bell, PhD, VP, Research
George B Abercrombe, SVP, Commercial Operations
Christopher Viehbacher, Pres. - Contact Info
-
Glaxo Wellcome Inc.
Phone: (919) 483-2100
5 Moore Drive
Research Triangle Park, NC 27709
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice